文献速递鼻科

美泊利单抗治疗重度慢性鼻窦炎伴鼻息肉的持续疗效:SYNAPSE 24周无治疗随访

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.
PubMed 文献 · Int Forum Allergy Rhinol · 2023-07-18

SYNAPSE III期研究52周显示美泊利单抗每4周皮下注射100mg可减小鼻息肉、改善症状与生活质量并减少激素使用和手术。停药后24周随访中,美泊利单抗组鼻息肉评分和手术比例优于安慰剂且部分持续,血嗜酸性粒细胞计数已回到基线。

要点

  • 停药24周后美泊利单抗组鼻息肉评分变化仍优于安慰剂。
  • 第76周鼻窦手术比例美泊利单抗组9% vs 安慰剂组31%。
  • 总体症状、生活质量及激素使用的改善在停药后部分持续。

核心结论

  • 52周美泊利单抗治疗在重度慢性鼻窦炎伴鼻息肉患者停药后24周仍与持续临床获益相关,医生做治疗决策时应考虑这一点。

研究设计与样本

  • SYNAPSE III期研究52周治疗后的24周无治疗随访分析。
  • 随访患者共134例,比较美泊利单抗与安慰剂从基线至第52周及第76周的变化。

主要发现

  • 鼻息肉评分自基线变化均值(95%CI):第52周美泊利单抗组-1.3(-1.8至-0.9)vs 安慰剂组-0.3(-0.6至0.1)。
  • 鼻息肉评分自基线变化均值(95%CI):第76周美泊利单抗组-1.2(-1.6至-0.7)vs 安慰剂组-0.1(-0.5至0.3)。
  • 接受鼻窦手术的患者比例:第52周美泊利单抗组4% vs 安慰剂组25%;第76周美泊利单抗组9% vs 安慰剂组31%。
  • 停药24周后血嗜酸性粒细胞计数已回到基线。
  • 美泊利单抗组总体症状、生活质量及糖皮质激素使用相对安慰剂的改善在第76周部分持续。

临床怎么用

  • 原文结论指出医生做治疗决策时应考虑52周美泊利单抗治疗停药后24周仍与持续临床获益相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the 52-week Phase III SYNAPSE study, mepolizumab given every 4 weeks (100 mg subcutaneously) reduced nasal polyp (NP) size, improved symptoms and quality of life (QoL), and reduced corticosteroid use and number of sinus surgeries in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), versus placebo. Because the durability of mepolizumab's efficacy after discontinuation is poorly understood in CRSwNP, the efficacy of mepolizumab after discontinuation was analyzed in severe CRSwNP, over a 24-week follow-up. METHODS: Changes from SYNAPSE baseline to end of treatment (week 52) and end of follow-up (week 76) were assessed for total endoscopic NP score, nasal obstruction and overall symptoms visual analog scale scores, and 22-item Sino-Nasal Outcome Test score. Time to first sinus surgery, time to first corticosteroid use, and geometric mean blood eosinophil counts (BECs) were also assessed. RESULTS: Among 134 follow-up patients, clinical improvements observed with mepolizumab versus placebo were partially evident 24 weeks after discontinuation despite BEC returning to baseline. The mean (95% confidence interval [CI]) change from baseline in NP score (week 52: -1.3 [1.8 to -0.9] vs. -0.3 [-0.6 to 0.1]; week 76: -1.2 [-1.6 to -0.7] vs. -0.1 [-0.5 to 0.3]) and the proportion of patients having sinus surgery (week 52: 4% vs. 25%; week 76: 9% vs. 31%) remained substantially improved with mepolizumab versus placebo. Mepolizumab-associated improvements in overall symptoms, quality of life, and corticosteroid use versus placebo were partially sustained at week 76. CONCLUSION: Fifty-two weeks of mepolizumab treatment is associated with sustained clinical benefits up to 24 weeks after discontinuation in patients with severe CRSwNP, which should be considered by physicians when making treatment decisions.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Desrosiers M, Diamant Z, Castelnuovo P, et al. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up. Int Forum Allergy Rhinol. 2023. PMID: 37345861. doi:10.1002/alr.23219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。